Intranasal Carbetocin Reduces Hyperphagia, Anxiousness and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial.
Elizabeth RoofCheri L DealShawn E McCandlessRonald L CowanJennifer L MillerJill K HamiltonElizabeth R RoederShana E McCormackTamanna R Roshan LalHussein D Abdul-LatifAndrea M HaqqKathryn S ObrynbaLaura C TorchenAlaina P VidmarDavid H ViskochilJean-Pierre ChanoineCarol K L LamMelinda J PierceLaurel L WilliamsLynne M BirdMerlin G ButlerDiane E JensenSusan E MyersOliver J OatmanCharumathi BaskaranLaura J ChalmersCary FuNathalie AlosScott D McLeanAjay ShahBarbara Y WhitmanBrent A BlumensteinSarah F LeonardJessica P ErnestJoseph W CormierSara P CotterDavis C RymanPublished in: The Journal of clinical endocrinology and metabolism (2023)
Carbetocin was well tolerated, and the 3.2 mg dose was associated with clinically meaningful improvements in hyperphagia and anxiousness and distress behaviors in participants with PWS.